NCT02671097View on ClinicalTrials.gov

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2016

Study Completion Date

August 31, 2016

Conditions

Healthy VolunteersPharmacokineticsDrug Interaction

Interventions

DRUG

Rosuvastatin

5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.

DRUG

BAY1841788 (ODM-201)

600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.

Trial Locations (1)

13353

CRS Clinical Research Services Berlin GmbH, Berlin